RxDoctor Payments Data

Chelsea Schwartz

Psychiatric/Mental Health · Pewaukee, WINPI 1942818588

Payments from drug & device makers

$741in general payments, 2019–2025

Across 32 payments — averaging $23.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$194
  • Corium, LLC$175
  • Teva Pharmaceuticals USA, Inc.$175
  • Supernus Pharmaceuticals, Inc.$97
  • USWM, LLC$58
  • Neurocrine Biosciences, Inc.$25
  • plus $18 from 1 others

What the payments were for

  • Food & beverage$63085%
  • Education$11115%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$741 in reported general payments places this provider in the 65th percentile of 384 psychiatric/mental health providers in Wisconsin.

See all psychiatric/mental health providers in Wisconsin

Medicare billing

Part B allowed, 2024
$26,212
Medicare patients
38
Services billed
433

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine57$341,809
AustedoDeutetrabenazine24$145,399
IngrezzaValbenazine Tosylate12$102,549
Invega SustennaPaliperidone Palmitate29$73,714
NuedextaDextromethorphan Hbr/Quinidine47$70,277
RexultiBrexpiprazole42$61,297
VraylarCariprazine Hcl39$53,545
CaplytaLumateperone Tosylate29$44,156
VyvanseLisdexamfetamine Dimesylate46$18,134
GeodonZiprasidone Hcl20$16,476
QuliptaAtogepant13$15,588
SuboxoneBuprenorphine Hcl/Naloxone Hcl15$10,640
BelsomraSuvorexant23$10,147
ZubsolvBuprenorphine Hcl/Naloxone Hcl24$9,558
Aripiprazole79$9,480

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo$175$487,20881 claims
Neurocrine Biosciences, Inc.Ingrezza$25$102,54912 claims
AbbVieVraylar, Qulipta, Namzaric$194$76,12664 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 384 psychiatric/mental health providers in Wisconsin.

Other psychiatric/mental health in Pewaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →